Fatal Fulminant Hepatitis from Rituximab-induced Hepatitis B Reactivation in a Patient with Follicular Lymphoma: A Case Report and a Brief Review of Literature
Zarak H Khan, Kamran Ilyas, Haider Ghazanfar, Hamza H Khan, Qulsoom Hussain, Sahla Hammad, Ahmed Munir, Rizwan Asim, Zarak H Khan, Kamran Ilyas, Haider Ghazanfar, Hamza H Khan, Qulsoom Hussain, Sahla Hammad, Ahmed Munir, Rizwan Asim
Abstract
The objective of our study was to recognize hepatitis B reactivation as a complication of rituximab chemotherapy and to realize the importance of screening for prior Hepatitis B virus (HBV) exposure in all patients with hematologic malignancies who will receive rituximab as part of their therapy. Rituximab is a monoclonal antibody targeting CD 20 receptors on the membrane of B cells. In this case report, we described a 79-year-old man who presented to our department with nausea, fatigue, and jaundice. Two months ago, he had received the last dose of the chemotherapy regimen containing rituximab for follicular B cell lymphoma. Ultrasound and computed tomography (CT) scan of abdomen did not show any focal lesions. Liver function tests showed worsening hepatic failure and viral serology demonstrated active HBV infection. Antiviral therapy with entecavir and tenofovir disoproxil fumarate failed to improve his symptoms, and he died of fulminant hepatic failure. Rituximab targets CD 20 receptors positive B cells. It can destroy both cancerous and normal B cells. A decline in immune function can activate occult HBV infection. Prior to initiation of rituximab therapy, screening should be conducted in all cases for HBV associated serological markers. Patients with active or occult HBV infection must be started on appropriate antiviral therapy to prevent any severe outcomes with rituximab-containing regimens.
Keywords: follicular lymphoma; hematologic malignancies; hepatitis b; rituximab; viral hepatitis.
Conflict of interest statement
The authors have declared that no competing interests exist.
References
- Anti-CD 20 monoclonal antibody (rituximab) treatment for inflammatory ocular diseases. Miserocchi E, Pontikaki I, Modorati G, Gattinara M, Meroni PL, Gerloni V. Autoimmun Rev. 2011;11:35–39.
- B-lymphocyte reconstitution after repeated rituximab treatment in a child with steroid-dependent autoimmune hemolytic anemia. van der Linde AA, Schatorjé EJ, van der Weij AM, Gemen EF, de Vries E. Pediatr Rep. 2011;3:0.
- Hepatitis B reactivation and rituximab in the oncology practice. Villadolid J, Laplant KD, Markham MJ, Nelson DR, George TJ Jr. Oncologist. 2010;15:1113–1121.
- Prevention of hepatitis B reactivation in the setting of immunosuppression. Pattullo V. Clin Mol Hepatol. 2016;22:219–237.
- A study of hepatitis B virus reactivation associated with rituximab therapy in real-world clinical practice: a single-center experience. Oh MJ, Lee HJ. Clin Mol Hepatol. 2013;19:51–59.
- Hepatitis B virus reactivation and hepatitis in diffuse large B-cell lymphoma patients with resolved hepatitis B receiving rituximab-containing chemotherapy: risk factors and survival. Chen KL, Chen J, Rao HL, et al. Chin J Cancer. 2015;34:225–234.
- Effect of prophylactic lamivudine for chemotherapy-associated hepatitis B reactivation in lymphoma: a meta-analysis of published clinical trials and a decision tree addressing prolonged prophylaxis and maintenance. Ziakas PD, Karsaliakos P, Mylonakis E. Haematologica. 2009;94:998–1005.
- Management of hepatitis B: summary of a clinical research workshop. Hoofnagle JH, Doo E, Liang TJ, Fleischer R, Lok AS. Hepatology. 2007;45:1056–1075.
- Current trends in management of hepatitis B virus reactivation in the biologic therapy era. Mastroianni CM, Lichtner M, Citton R, et al. World J Gastroenterol. 2011;17:3881–3887.
- Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab. Yeo W, Chan TC, Leung NW, et al. J Clin Oncol. 2009;27:605–611.
Source: PubMed